RxDoctor Payments Data

Alain Zingraff Lekoubou Looti, MD

Neurology · Hershey, PANPI 1174963888

Payments from drug & device makers

$18,099in general payments, 2019–2025

Across 22 payments — averaging $822.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Ceribell, Inc.$15K
  • Neuropace, Inc.$2K
  • Livanova USA, Inc.$404
  • UCB, Inc.$297
  • Greenwich Biosciences, Inc.$231
  • Neurelis, Inc.$58
  • plus $44 from 1 others

What the payments were for

  • Consulting fees$15,22584%
  • Travel & lodging$1,1586%
  • Food & beverage$1,7169%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,099 in reported general payments places this provider in the 75th percentile of 941 neurology providers in Pennsylvania.

See all neurology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$45,024
Medicare patients
383
Services billed
432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)46$295,419
LamictalLamotrigine47$80,008
TopamaxTopiramate16$30,428
Lacosamide156$29,284
Rufinamide12$20,090
VimpatLacosamide17$19,356
Clobazam98$17,425
XcopriCenobamate16$14,796
FycompaPerampanel12$13,710
Lamotrigine ErLamotrigine23$11,874
Carbamazepine ErCarbamazepine84$11,612
TrileptalOxcarbazepine12$11,219
Levetiracetam276$11,147
Divalproex Sodium ErDivalproex Sodium121$8,881
Depakote ErDivalproex Sodium12$6,708

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
UCB, Inc.Vimpat$297$19,35617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 941 neurology providers in Pennsylvania.

Other neurology in Hershey

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →